Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California


Purpose:

The purpose of this study is to investigate safety and tolerability after high Single Ascending Oral Doses of AZD1656.


Criteria:

Inclusion Criteria: - Provision of signed and dated, written informed consent prior to any study specific procedures. - Male, T2DM patients aged 20-60 years - Treatment with 1 to 2 OADs as Therapy for T2DM for at least 30 days prior to enrollment - Patients should not have been treated with glitazones within 6 months prior to enrollment - Male T2DM patients without known cardiovascular disease, with the exception of Grade 1 hypertension without secondary organ involvement (eg. grade 1 HT is allowed if no eye, kidney disease or LVH has been documented). Exclusion Criteria: - History of ischemic heart disease , heart failure, stroke, transitory ischemic attack or peripheral vascular disease. - Prolonged QTcF>450 msec or shortened QTcF<350 msec or family history of long QT syndrome. - Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. - Systolic BP>159 mmHg or diastolic BP>99 mmHg at screening and on Day-1


NCT ID:

NCT01221545


Primary Contact:

Principal Investigator
Linda Morrow, MD
Profil Institute for Clinical Research, Inc.


Backup Contact:

N/A


Location Contact:

Chula Vista, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.